A Systematic Framework for Prioritizing Burden of Disease Data Required for Vaccine Development and Implementation: The Case for Group A Streptococcal Diseases . (19th April 2022)

• Record Type: Journal Article
• Authors: Moore, Hannah C; Cannon, Jeffrey W; Kaslow, David C; Lamagni, Theresa; Bowen, Asha C; Miller, Kate M; Cherian, Thomas; Carapetis, Jonathan; Van Beneden, Chris
• Is Part Of: Clinical infectious diseases. Volume 75:Number 7(2022)
• Page Start: 1245
• Page End: 1254
• Publication Date: 2022-04-19
• Subjects: burden of disease -- vaccine policy -- vaccine development -- group A streptococcal diseases; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciac291
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Vaccine development and implementation decisions need to be guided by accurate and robust burden of disease data. We developed an innovative systematic framework outlining the properties of such data that are needed to advance vaccine development and evaluation, and prioritize research and surveillance activities. We focus on 4 objectives—advocacy, regulatory oversight and licensure, policy and post-licensure evaluation, and post-licensure financing—and identify key stakeholders and specific requirements for burden of disease data aligned with each objective. We apply this framework to group A Streptococcus, a pathogen with an underrecognized global burden, and give specific examples pertinent to 8 clinical endpoints. This dynamic framework can be adapted for any disease with a vaccine in development and can be updated as vaccine candidates progress through clinical trials. This framework will also help with research and innovation priority setting of the Immunization Agenda 2030 (IA2030) and accelerate development of future vaccines. Abstract : We introduce an innovative systematic framework prioritizing burden of disease data requirements for vaccines through advocacy, regulatory and licensing, policy and post-introduction evaluation, and financing. We apply this framework to group A Streptococcus to aid efforts to accelerate vaccine development.